Fig. 2: Antiproliferative response to treatment in all evaluable participants. | Nature Cancer

Fig. 2: Antiproliferative response to treatment in all evaluable participants.

From: Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial

Fig. 2

a, Percentage change in Ki67 for each participant, sorted from low to high. PR status, tumor grade, histological subtype, ER Allred score and baseline Ki67 are indicated in black and white boxes under each participant (n = 198). b, Individual changes in percentage Ki67 positivity from baseline to EOT. c, Pairwise comparisons of Ki67 suppression for participants in arms A (n = 51), B (n = 74) and C (n = 72), defined as the geometric mean of Ki67 proportional change (EOT/baseline − 1). Error bars represent the 95% CI. Statistical analysis was conducted using two-sided t-tests of the geometric means with either false discovery rate (FDR) or Bonferroni correction for multiple testing. d, Percentage change from baseline in AURKA positivity, sorted from low to high (n = 169 participants).

Source data

Back to article page